An interventional study of Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific) in Heart Failure With Preserved Ejection Fraction, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia — 5 open to participants now, 6 under way, 1 of them phase 3. Heart Failure · Fundación para la Investigación del Hospital Clínico de Valencia.
Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 7 with no phase, and was the 13th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia are open now, in 1 country. Recruiting first, the newest first:
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 60+ · Women only
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 64 across the 14 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fundación para la Investigación del Hospital Clínico de Valencia is the lead sponsor of 73 studies on the registry; 18 are open to participants now.
3 of the studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06992089Fundación para la Investigación del Hospital Clínico de ValenciaSHort Of Pace - Heart Failure (SHOP-HF) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed as a multicenter, prospective, controlled, randomized, two-arms, cross-over, two parallel cohorts, efficacy Clinical research with CE-marked medical device . The crossover trial will be performed in a blind fashion, so each participant will be evaluated during both blinded pacing-on and pacing-off phases, each of which will last 3 months. The population includes patients with the diagnosis of stable HFpEF according to criteria of the European Society of Cardiology and New York Heart Association (NYHA) functional class II-III/IV, left ventricular hypertrophy with small ventricular volume, sinus rhythm with low basal heart rate and chronotropic incompetence (CI).
All patients will undergo pacemaker implantation, and computer-generated randomization sequence previously designed will be used to allocate participants (in a 1:1 ratio) to receive: (a) programming of the pacemaker with pacing On followed by pacing Off in two periods of 3 months; or (b) programming of the pacemaker with pacing Off followed by pacing On in two periods of 3 months. The study will be conducted in three centers in Spain. Discounting the time due to staggered entry, the total duration of a patient's follow-up will be 7 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis criteria of HFpEF according to ESC guidelines:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pacemaker stimulation programmed as AAIR / DDDR / VVIR with the basic stimulation frequency and the rate response as follows (pacing on): * Basic heart rate: derived from the averaged resting heart rates of healthy adults according to height and LVEF. * Rate response through a combination of minute ventilation and accelerometer, with an accelerometer response factor between 3 and 8 and an activity threshold ranging from medium-low to medium. Within these ranges, settings will be individualised by the investigator according to the participant's chronotropic response, activity profile and clinical tolerance. Each adjustment will be documented in the source records and case report form. These programming criteria will also apply when pacing-on is initiated at crossover.
Device: Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)
VVI 30 bpm
Device: Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)
Dual-chamber cardiac pacemaker (Proponent MRI L211, Proponent MRI L231, Accolade MRI L311 or Accolade MRI L331, Boston Scientific), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™+ MRI pacing lead) and right ventricular lead (INGEVITY™+ MRI pacing lead). Single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific), with rate-adaptive pacing of the ventricles. There will be an associated right ventricular lead (INGEVITY™+ MRI pacing lead).
Peak oxygen uptake
The primary endpoint of the study is absolute and relative changes in peak oxygen uptake (peakVO2) after three months of pacemaker stimulation.
Time frame: 3 months after the pacemarker stimulation
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Absolute changes in quality of live assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Time frame: From randomization until the end of study in month 7
E/E' ratio
Absolute changes in echocardiogram parameters (E/E' ratio)
Time frame: From baseline until the end of study in month 7
Left ventricular volume index
Absolute changes in echocardiogram parameters (Left ventricular volume index)
Time frame: From baseline until the end of study in month 7
Left atrial volume index
Absolute changes in echocardiogram parameters (Left atrial volume index)
Time frame: From baseline until the end of study in month 7
Pro-B-type natriuretic peptide
Absolute and relative changes in prognostic biomarkers (pro-B-type natriuretic peptide)
Time frame: From baseline until the end of study in month 7
Serum carbohydrate antigen 125
Absolute and relative changes in prognostic biomarkers (serum carbohydrate antigen 125).
Time frame: From baseline until the end of study in month 7
Acute HF hospitalizations
Total number of episodes of acute HF hospitalizations.
Time frame: From baseline until the end of study in month 7
Worsening HF not requiring hospitalization
Total episodes of worsening HF not requiring hospitalization
Time frame: From baseline until the end of study in month 7
Mortality
Mortality
Time frame: From baseline until the end of study in month 7
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Investigación del Hospital Clínico de Valencia